tirzepatide cvot results In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://nej.md/4qd5rLx SURPASS-CVOT Published: Large Trial Confirms

.) 500 25 C

Rapid Risk Reduction Seen in First Months The study found that semaglutide was associated with a 38% reduced risk of major adverse cardiovascular events (MACE) within the first 3 months compared to placebo (36 vs 58, respectively) Within the first 6 months, semaglutide was associated with a 41% reduced risk of MACE compared to placebo (67 vs 113, respectively) Notably, at 3 and 6 months, most patients had not yet lost much weight and many were not yet on the full target dose of semaglutide 2.4 mg weekly

By tracing the cross-peaks in the 1 H- 1 H correlation spectroscopy (COSY) spectrum (Extended Data Fig

Why Food Quality Matters More on GLP-1 Than Normal Dieting On a typical 2,000-calorie diet, a 300-calorie "wasted" choice is 15% of your day

How long do the effects of Kisspeptin-10 last

An unexpected detail is their similar gastrointestinal impact, despite different mechanisms, highlighting the need for monitoring